Add to Favorites

License-In / Co-Development Opportunities for China

The 30 products approved by FDA in 2011

Report Overview

The pharmaceutical industry is facing challenges,

Expiration of top selling products: e.g. Zyprexa, Lipitor, Plavix，Lovenox, etc.
High R & D expenditure of about 60 Bio.USD during the past three years.
Stricter FDA approval requirements with more supporting data.
More price controlling as result of the implemented China Medical Reform System especially for patent expired products responsible for a major part of revenues of most pharmaceutical MNCs in China.

Therefore, having innovative products with sufficient price protection is of key importance for winning with sustainable growth in the foreseeable future.


FDA has approved 26 new products in 2009, 21 new products in 2010 and 35 new products in 2011.


Based on Loudon’s in-house database, we selected the 30 approved products (NMEs) in 2011, which will benefit both MNCs and local companies from following perspectives:

MNCs may have opportunities to license in or obtain sales rights in China, if the company has no presence in China and the products not yet licensed out.
Local companies may license-in or co-develop it with originators, or after the necessary patent checks, they may have chances to start first the development of a generic copy in China.

This report describes information of each product, including their regulatory status, and their companies’ status in the China market. Moreover this report enables the readers to get an in depth understanding of the generics of those 30 products in China, thereby obtaining a comprehensive view for business decisions. Furthermore, this report analyzes the license-in opportunities based on each product’s characteristics.


Key Report Features

Report contains 30 products approved by FDA in 2011 in the following therapeutic areas:

Endocrinology 1
Urology 1
Oncology 8
Neurology 3
Cardiovascular 2
Genetic Disease 1
Hematology (cancer) 2
Psychiatry 1
Dermatology 1
Respiratory 2
Radiology 2
Diagnostic 1
Rheumatology 1
Infection 4
Antithrombotic 1
Ophthalmology 1

For each molecule, both product and company related information are presented to help companies to identify business development opportunities.


Product related information:

The brand, chemical names and company
Therapeutic area, mode of action, indication and formulation
Regulatory status FDA, EMEA, and China (SFDA)
Medical information and framework of pivotal clinical studies

Company related information:

Contact information
R & D platform
Other products in portfolio & pipeline
China presence.

The report contains 80 pages and is in Chinese presentation format. English version will be charged additionally.


Who Would Benefit From This Report?

CEOs
Sales & Marketing VPs
R & D
BD/Marketing/ Medical Directors
Researchers
Financial Analysts in pharmaceutical, medical device, health food, cosmetics
Private and institutional investors in life science industry

Publication date

August 15, 2012


Price

5,000 RMB or 800 USD per subscription.



*You can send E-mailEmail to LFE to purchase this report.


Please transfer the RMB or USD payments to the following account:

 

A/C: Shanghai Loudon Marketing Consultant Co., Ltd
A/C: No. 444259223258
Bank Name: Bank of China Shanghai, FanYu Road Sub-branch
Swift code: BKCHCNBJ300

 

Name Beneficiary：Loudon Far East B.V. The Netherlands
Bank Name：ING Bank N.V.
Account No：67.38.48.906
IBAN：NL23INGB 0673848906
BIC/SWIFT：INGBNL2A

 

 

 



Ordering application form

Step 1:

Please choose the report you are interested in, click "More information" button.

Step 2:

Please go through the brief introduction of the report carefully and click "E-mail" link in the end of the page.

Step 3:

Please finish filling your required information in the e-mail.

Step 4:

After sending E-mail to Loudon, our client service person will contact you afterwards.


*If any questions, please contact our client service person.

Tel: +86-21-6290 2121-107

Email: jenny.zhu@loudon-research.com

(All free during 10:00~18:00 every work-day)